MaxCyte to buy Akron Bio for $151.8M and secures up to $75M MidCap credit facility
MaxCyte (NASDAQ: MXCT) announced on November 10, 2026 a definitive agreement to acquire Akron BioProducts, a supplier of GMP-grade reagents and ancillary materials for cell therapy manufacturing, from Arcline Investment Management. Consideration is $105M in cash, about 20.6M MaxCyte shares and $20M in deferred payments, with closing expected before the end of 2026 and no stockholder approval needed. MaxCyte also arranged a MidCap Financial facility of up to $75M, and the combined company's products are referenced in drug master files supporting five approved therapies and over 100 clinical programs.
Company's press release (SEC filing): Maxcyte, Inc. ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
IndustryCompany release